Home
>
US Stocks
>
Oric Pharmaceuticals

Oric Pharmaceuticals (ORIC)

$5.15

-0.1

(-1.9%)▲

Market is closed - opens 7 PM, 12 Jun 2023

Insights on Oric Pharmaceuticals

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 43.0% return, outperforming this stock by 18.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 139.6% return, outperforming this stock by 224.5%

Performance

  • $5.07
    $5.26
    $5.15
    downward going graph

    1.55%

    Downside

    Day's Volatility :3.61%

    Upside

    2.09%

    downward going graph
  • $2.36
    $6.85
    $5.15
    downward going graph

    54.17%

    Downside

    52 Weeks Volatility :65.55%

    Upside

    24.82%

    downward going graph

Returns

PeriodOric PharmaceuticalsSector (Health Care)Index (Russel 2000)
3 Months
20.66%
4.7%
-0.2%
6 Months
59.63%
-5.8%
-1.5%
1 Year
24.11%
3.6%
-1.7%
3 Years
-85.2%
26.6%
20.6%

Highlights

Market Capitalization
248.5M
Book Value
$4.5
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.09
Wall Street Target Price
13.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-22.22%
Return On Equity TTM
-39.44%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-88.2M
Diluted Eps TTM
-2.09
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.17
EPS Estimate Next Year
-2.09
EPS Estimate Current Quarter
-0.54
EPS Estimate Next Quarter
-0.57

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Oric Pharmaceuticals(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
9
Hold
1
1
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 162.14%

Current $5.15
Target $13.50

Technicals Summary

Sell

Neutral

Buy

Oric Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Oric Pharmaceuticals
Oric Pharmaceuticals
0.0%
59.63%
24.11%
-85.2%
-80.05%
Moderna, Inc.
Moderna, Inc.
-4.5%
-24.34%
-1.71%
107.99%
571.72%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.07%
1.03%
31.18%
23.66%
140.46%
Novo Nordisk A/s
Novo Nordisk A/s
-5.39%
23.69%
43.02%
139.56%
255.68%
Seagen, Inc.
Seagen, Inc.
-2.64%
47.69%
39.68%
30.74%
191.76%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.99%
5.85%
30.48%
22.79%
123.76%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Oric Pharmaceuticals
Oric Pharmaceuticals
NA
NA
NA
-2.17
-0.39
-0.22
0.0
4.5
Moderna, Inc.
Moderna, Inc.
10.82
10.88
0.0
-1.74
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.15
20.15
9.01
41.59
0.19
0.1
0.0
219.38
Novo Nordisk A/s
Novo Nordisk A/s
41.07
41.07
2.03
4.99
0.84
0.23
0.01
4.44
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.89
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
25.51
25.51
0.41
14.57
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Oric Pharmaceuticals
Oric Pharmaceuticals
Buy
$248.5M
-80.05%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.6B
571.72%
10.82
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.0B
140.46%
20.15
33.81%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$356.5B
255.68%
41.07
32.47%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
191.76%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.1B
123.76%
25.51
35.4%

Institutional Holdings

  • FMR Inc

    8.91%

  • Column Group LLC

    7.91%

  • EcoR1 Capital, LLC

    7.58%

  • Alkeon Capital Management, LLC

    5.32%

  • Millennium Management LLC

    5.03%

  • Suvretta Capital Management, LLC

    4.22%

Corporate Announcements

  • Oric Pharmaceuticals Earnings

    Oric Pharmaceuticals’s price-to-earnings ratio stands at None

    Read More

Company Information

oric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.

Organization
Oric Pharmaceuticals
Employees
88
CEO
Dr. Richard A. Heyman Ph.D.
Industry
Health Technology

Discover More

FAQs